✦ LIBER ✦

Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment

✍ Scribed by Frederic Peyrade; Antoine Italiano; Xavier Fontana; Isabelle Peyrottes; Antoine Thyss

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radioimmunotherapy with131I-Rituximab in

✍ Kang, Geon Wook; Kang, Hye Jin; Shin, Dong-Yeop; Gu, Ha Ra; Choi, Hong Seok; Lim 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 132 KB

Fludarabine and mitoxantrone followed by

✍ Pier Luigi Zinzani; Monica Tani; Alessandro Pulsoni; Marco Gobbi; Alessio Perott 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 119 KB

Use of Ibritumomab Tiuxetan Anti-CD20 Ra

✍ Tsai, Donald E.; Maillard, Ivan; Schuster, Stephen J.; Nasta, Sunita D.; Porter, 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 478 KB

Antilymphoma Treatments Given Subsequent

✍ Ansell, Stephen M.; Schilder, Russell J.; Pieslor, Peter C.; Gordon, Leo I.; Emm 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 111 KB

PCN115 COST UTILITY ANALYSIS OF 90Y-IBRI

✍ SG Eggington; C Piñol; E Musi; A Valderrama 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB